Management of chordoma and chondrosarcoma with definitive dose-escalated single-fraction spine stereotactic radiosurgery
Journal of Neuro-Oncology · 2023-09 · 164 (2) · 377-386
DOI: 10.1007/s11060-023-04432-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, online erschienen am 04.09.2023. Verfasst von Alexander D Sherry und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Bldv, Unit 1202, 7…. Hauptthemen laut MEDLINE: Radiosurgery, Chordoma, Chondrosarcoma, Bone Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
PURPOSE: The management of chordoma or chondrosarcoma involving the spine is often challenging due to adjacent critical structures and tumor radioresistance. Spine stereotactic radiosurgery (SSRS) has radiobiologic advantages compared with conventional radiotherapy, though there is limited evidence on SSRS in this population. We sought to characterize the long-term local control (LC) of patients treated with SSRS. METHODS: We retrospectively reviewed patients with chordoma or chondrosarcoma treated with dose-escalated SSRS, defined as 24 Gy in 1 fraction to the gross tumor volume. Overall survival (OS) was calculated by Kaplan-Meier functions. Competing risk analysis using the cause-specific hazard function estimated LC time. RESULTS: Fifteen patients, including 12 with chordoma and 3 with chondrosarcoma, with 22 lesions were included. SSRS intent was definitive, single-modality in 95% of cases (N = 21) and post-operative in 1 case (5%). After a median censored follow-up time of 5 years (IQR 4 to 8 years), median LC time was not reached (IQR 8 years to not reached), with LC rates of 100%, 100%, and 90% at 1 year, 2 years, and 5 years. The median OS was 8 years (IQR 3 years to not reached). Late grade 3 toxicity occurred after 23% of treatments (N = 5, fracture), all of which were managed successfully with stabilization. CONCLUSION: Definitive dose-escalated SSRS to 24 Gy in 1 fraction appears to be a safe and effective treatment for achieving durable local control in chordoma or chondrosarcoma involving the spine, and may hold particular importance as a low-morbidity alternative to surgery in selected cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Bldv, Unit 1202, 77030, Houston, TX, USA.
- Department of Musculoskeletal Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Radiation Physics, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Neurosurgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Bldv, Unit 1202, 77030, Houston, TX, USA. AJGhia@mdanderson.org.
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Sherry, A. D., Maroongroge, S., De, B., Amini, B., Conley, A. P., Bishop, A. J., Wang, C., Beckham, T., Tom, M., Briere, T., Li, J., Yeboa, D. N., McAleer, M. F., North, R., Tatsui, C. E., Rhines, L. D., & Ghia, A. J. (2023). Management of chordoma and chondrosarcoma with definitive dose-escalated single-fraction spine stereotactic radiosurgery. Journal of Neuro-Oncology, 164(2), 377-386. https://doi.org/10.1007/s11060-023-04432-1
Vancouver
Sherry AD, Maroongroge S, De B, Amini B, Conley AP, Bishop AJ, et al. Management of chordoma and chondrosarcoma with definitive dose-escalated single-fraction spine stereotactic radiosurgery. Journal of Neuro-Oncology. 2023;164(2):377-386. doi:10.1007/s11060-023-04432-1
BibTeX
@article{Sherry2023,
author = {Sherry, Alexander D and Maroongroge, Sean and De, Brian and Amini, Behrang and Conley, Anthony P and Bishop, Andrew J and Wang, Chenyang and Beckham, Thomas and Tom, Martin and Briere, Tina and Li, Jing and Yeboa, Debra N and McAleer, Mary Frances and North, Robert and Tatsui, Claudio E and Rhines, Laurence D and Ghia, Amol J},
title = {Management of chordoma and chondrosarcoma with definitive dose-escalated single-fraction spine stereotactic radiosurgery},
journal = {Journal of Neuro-Oncology},
year = {2023},
volume = {164},
number = {2},
pages = {377--386},
doi = {10.1007/s11060-023-04432-1}
}
EUVIMED